Pleno

Pleno is a private, pre-revenue biotech company developing a disruptive genomics platform called Hypercoding, which is designed to detect multi-omic biomarkers (DNA, RNA, methylation, protein) with unprecedented speed, scale, and cost-efficiency. Its core product is the RAPTOR instrument, which combines advanced biochemical probes with signal processing algorithms derived from telecommunications to decode vast amounts of genetic information from a sample. The company aims to democratize clinical genomics by addressing the critical bottlenecks of total cost, turnaround time, and workflow complexity that currently limit market penetration in oncology and other areas. Pleno is positioned as a platform and diagnostics company targeting the vast, untapped market for routine clinical genomic testing.

Hypercoding™ technology, which combines telecommunications-derived coding techniques with biochemistry to detect 10-10,000 multi-omic biomarkers (DNA, RNA, methylation, protein) via circularizable probe (Plenoid) capture, in-situ amplification, and optical decoding on the RAPTOR instrument.

Pleno competes directly with established genomic testing modalities: Next-Generation Sequencing (e.g., Illumina, Thermo Fisher), PCR (e.g., Roche, Qiagen), and microarrays. Its value proposition is superior multiplexing capability and lower total cost compared to NGS, and higher plex and multi-omic capacity compared to PCR.